Trivalent ultrashort lipopeptides are potent pH dependent antifungal agents

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1296-1302

  Arnusch, Christopher J ^a   Albada, H Bauke ^b   Van Vaardegem, Martin ^b   Liskamp, Rob M J ^b   Sahl, Hans Georg ^c   Shadkchan, Yana ^d   Osherov, Nir ^d   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; LIPOPEPTIDE; TRIVALENT ULTRASHORT LIPOPEPTIDE; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LD 50; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CELL LINE; CRYPTOCOCCUS NEOFORMANS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEMOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOPEPTIDES; LUNG; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NANOSTRUCTURES; POLYMERS; PULMONARY ASPERGILLOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856934640     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2014474     Document Type: Article

References (50)

1. Zasloff, M. Antimicrobial peptides of multicellular organisms Nature 2002, 415, 389-395 (Pubitemid 34100944)
2. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol. 2005, 3, 238-250 (Pubitemid 40298223)
3. Boman, H. G. Antibacterial peptides: key components needed in immunity Cell 1991, 65, 205-207 (Pubitemid 121006052)
4. Hancock, R. E.; Falla, T.; Brown, M. Cationic bactericidal peptides Adv. Microb. Physiol. 1995, 37, 135-175
5. Wimley, W. C.; Hristova, K. Antimicrobial Peptides: Successes, Challenges and Unanswered Questions J. Membr. Biol. 2011, 1-8
6. Makovitzki, A.; Shai, Y. pH-Dependent Antifungal Lipopeptides and Their Plausible Mode of Action Biochemistry 2005, 44, 9775-9784 (Pubitemid 40994371)
7. Hunt, J. F.; Fang, K.; Malik, R.; Snyder, A.; Malhotra, N.; Platts-Mills, T. A.; Gaston, B. Endogenous airway acidification. Implications for asthma pathophysiology Am. J. Respir. Crit. Care Med. 2000, 161, 694-699 (Pubitemid 30171718)
8. Tannock, I. F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 1989, 49, 4373-4384 (Pubitemid 19208329)
9. Oppenheim, F. G.; Xu, T.; McMillian, F. M.; Levitz, S. M.; Diamond, R. D.; Offner, G. D.; Troxler, R. F. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans J. Biol. Chem. 1988, 263, 7472-7477
10. Tsai, H.; Bobek, L. A. Human salivary histatins: promising anti-fungal therapeutic agents Crit. Rev. Oral Biol. Med. 1998, 9, 480-497 (Pubitemid 29402012)
11. Lee, I. H.; Cho, Y.; Lehrer, R. I. Effects of pH and salinity on the antimicrobial properties of clavanins Infect. Immun. 1997, 65, 2898-2903 (Pubitemid 27264123)
12. van Kan, E. J.; Demel, R. A.; Breukink, E.; van der Bent, A.; de Kruijff, B. Clavanin permeabilizes target membranes via two distinctly different pH-dependent mechanisms Biochemistry 2002, 41, 7529-7539 (Pubitemid 34627779)
13. Oudhoff, M. J.; Kroeze, K. L.; Nazmi, K.; van den Keijbus, P. A.; van 't Hof, W.; Fernandez-Borja, M.; Hordijk, P. L.; Gibbs, S.; Bolscher, J. G.; Veerman, E. C. Structure-activity analysis of histatin, a potent wound healing peptide from human saliva: cyclization of histatin potentiates molar activity 1000-fold FASEB J. 2009, 23, 3928-3935
14. Oudhoff, M. J.; Bolscher, J. G.; Nazmi, K.; Kalay, H.; van 't Hof, W.; Amerongen, A. V.; Veerman, E. C. Histatins are the major wound-closure stimulating factors in human saliva as identified in a cell culture assay FASEB J. 2008, 22, 3805-3812
15. Kacprzyk, L.; Rydengard, V.; Morgelin, M.; Davoudi, M.; Pasupuleti, M.; Malmsten, M.; Schmidtchen, A. Antimicrobial activity of histidine-rich peptides is dependent on acidic conditions Biochim. Biophys. Acta 2007, 1768, 2667-2680 (Pubitemid 350060862)
16. Tu, Z.; Young, A.; Murphy, C.; Liang, J. F. The pH sensitivity of histidine-containing lytic peptides J. Pept. Sci. 2009, 15, 790-795
17. Li, L.; He, J.; Eckert, R.; Yarbrough, D.; Lux, R.; Anderson, M.; Shi, W. Design and Characterization of an Acid-Activated Antimicrobial Peptide Chem. Biol. Drug Des. 2010, 75, 127-132
18. Mason, A. J.; Gasnier, C.; Kichler, A.; Prevost, G.; Aunis, D.; Metz-Boutigue, M. H.; Bechinger, B. Enhanced membrane disruption and antibiotic action against pathogenic bacteria by designed histidine-rich peptides at acidic pH Antimicrob. Agents Chemother. 2006, 50, 3305-3311 (Pubitemid 44527502)
19. Mason, A. J.; Leborgne, C.; Moulay, G.; Martinez, A.; Danos, O.; Bechinger, B.; Kichler, A. Optimising histidine rich peptides for efficient DNA delivery in the presence of serum J. Controlled Release 2007, 118, 95-104 (Pubitemid 46283102)
20. Langlet-Bertin, B.; Leborgne, C.; Scherman, D.; Bechinger, B.; Mason, A. J.; Kichler, A. Design and evaluation of histidine-rich amphipathic peptides for siRNA delivery Pharm. Res. 2010, 27, 1426-1436
21. Rydengard, V.; Andersson Nordahl, E.; Schmidtchen, A. Zinc potentiates the antibacterial effects of histidine-rich peptides against Enterococcus faecalis FEBS J. 2006, 273, 2399-2406 (Pubitemid 43736654)
22. Makovitzki, A.; Fink, A.; Shai, Y. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides Cancer Res. 2009, 69, 3458-3463
23. Chongsiriwatana, N. P.; Miller, T. M.; Wetzler, M.; Vakulenko, S.; Karlsson, A. J.; Palecek, S. P.; Mobashery, S.; Barron, A. E. Short alkylated peptoid mimics of antimicrobial lipopeptides Antimicrob. Agents Chemother. 2011, 55, 417-420
24. Marsh, E. N.; Buer, B. C.; Ramamoorthy, A. Fluorine-a new element in the design of membrane-active peptides Mol. Biosyst. 2009, 5, 1143-1147
25. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 15997-16002 (Pubitemid 44657581)
26. Makovitzki, A.; Baram, J.; Shai, Y. Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action Biochemistry 2008, 47, 10630-10636
27. Arnusch, C. J.; Branderhorst, H.; de Kruijff, B.; Liskamp, R. M. J.; Breukink, E.; Pieters, R. J. Enhanced membrane pore formation by multimeric/oligomeric antimicrobial peptides Biochemistry 2007, 46, 13437-13442 (Pubitemid 350136382)
28. Sal-Man, N.; Oren, Z.; Shai, Y. Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells Biochemistry 2002, 41, 11921-11930
29. Pieters, R. J.; Arnusch, C. J.; Breukink, E. Membrane permeabilization by multivalent anti-microbial peptides Protein Pept. Lett. 2009, 16, 736-742
30. Monnee, M. C.; Brouwer, A. J.; Verbeek, L. M.; van Wageningen, A. M.; Liskamp, R. M. J. Bio-inspired synthetic receptor molecules towards mimicry of vancomycin Bioorg. Med. Chem. Lett. 2001, 11, 1521-1525 (Pubitemid 32703555)
31. Albada, H. B.; Liskamp, R. M. J. TAC-scaffolded tripeptides as artificial hydrolytic receptors: a combinatorial approach toward esterase mimics J. Comb. Chem. 2008, 10, 814-824
32. Hijnen, M.; van Zoelen, D. J.; Chamorro, C.; van Gageldonk, P.; Mooi, F. R.; Berbers, G.; Liskamp, R. M. J. A novel strategy to mimic discontinuous protective epitopes using a synthetic scaffold Vaccine 2007, 25, 6807-6817 (Pubitemid 47337131)
33. van Zoelen, D. J.; Egmond, M. R.; Pieters, R. J.; Liskamp, R. M. J. Synthesis and evaluation of TAC-based inhibitors of papain as mimics of cystatin B ChemBioChem 2007, 8, 1950-1956
34. Chamorro, C.; Kruijtzer, J. A.; Farsaraki, M.; Balzarini, J.; Liskamp, R. M. J. A general approach for the non-stop solid phase synthesis of TAC-scaffolded loops towards protein mimics containing discontinuous epitopes Chem. Commun. 2009, 821-823
35. Tu, Z.; Hao, J.; Kharidia, R.; Meng, X. G.; Liang, J. F. Improved stability and selectivity of lytic peptides through self-assembly Biochem. Biophys. Res. Commun. 2007, 361, 712-717 (Pubitemid 47243619)
36. Opatz, T.; Liskamp, R. M. J. A selectively deprotectable triazacyclophane scaffold for the construction of artificial receptors Org. Lett. 2001, 3, 3499-3502 (Pubitemid 33625394)
37. Albada, H. B.; Soulimani, F.; Weckhuysen, B. M.; Liskamp, R. M. J. Scaffolded amino acids as a close structural mimic of type-3 copper binding sites Chem. Commun. 2007, 4895-4897
38. Albada, H. B.; Arnusch, C. J.; Branderhorst, H. M.; Verel, A. M.; Janssen, W. T. M.; Breukink, E.; de Kruijff, B.; Pieters, R. J.; Liskamp, R. M. J. Potential scorpionate antibiotics: Targeted hydrolysis of lipid II containing model membranes by vancomycin-TACzyme conjugates and modulation of their antibacterial activity by Zn-ions Bioorg. Med. Chem. Lett. 2009, 19, 3721-3724
39. Beauvais, A.; Latge, J. P. Membrane and cell wall targets in Aspergillus fumigatus Drug Resist. Updates 2001, 4, 38-49 (Pubitemid 32267824)
40. Arnusch, C. J.; Ulm, H.; Josten, M.; Shadkchan, Y.; Osherov, N.; Sahl, H. G.; Shai, Y. Ultrashort peptide bioconjugates are exclusively antifungal agents and synergize with cyclodextrin and amphotericin B Antimicrob. Agents Chemother. 2012, 56, 1-9
41. Chen, Y.; Guarnieri, M. T.; Vasil, A. I.; Vasil, M. L.; Mant, C. T.; Hodges, R. S. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides Antimicrob. Agents Chemother. 2007, 51, 1398-1406 (Pubitemid 46586822)
42. Helmerhorst, E. J.; Reijnders, I. M.; van't Hof, W.; Simoons-Smit, I.; Veerman, E. C.; Amerongen, A. V. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides Antimicrob. Agents Chemother. 1999, 43, 702-704 (Pubitemid 29109547)
43. Diamond, R. D. Fungal surfaces: effects of interactions with phagocytic cells Rev. Infect. Dis. 1988, 10 (Suppl 2) S428-S431
44. Schaffner, A.; Douglas, H.; Braude, A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes J. Clin. Invest. 1982, 69, 617-631 (Pubitemid 12184959)
45. Gold, J. W. Opportunistic fungal infections in patients with neoplastic disease Am. J. Med. 1984, 76, 458-463 (Pubitemid 14159557)
46. Cohen, M. S.; Isturiz, R. E.; Malech, H. L.; Root, R. K.; Wilfert, C. M.; Gutman, L.; Buckley, R. H. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi Am. J. Med. 1981, 71, 59-66 (Pubitemid 12254714)
47. Ramamoorthy, A. Beyond NMR spectra of antimicrobial peptides: dynamical images at atomic resolution and functional insights Solid State Nucl. Magn. Reson. 2009, 35, 201-207
48. Arnusch, C. J.; Bonvin, A. M.; Verel, A. M.; Jansen, W. T.; Liskamp, R. M. J.; de Kruijff, B.; Pieters, R. J.; Breukink, E. The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci Biochemistry 2008, 47, 12661-12663
49. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard 2nd ed., M38-A2; Clinical and Laboratory Standards Institute: Wayne, PA, 2008.
50. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A3; Clinical and Laboratory Standards Institute: Wayne, PA, 2008.